Molecular Pharmacology (USA), Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLPH research report →
About the company
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd.
- CEO
- Jeffrey David Edwards
- IPO
- 2009
- Employees
- 1
- HQ
- Perth, WA, AU
Price Chart
- Market Cap
- $403.82K
- P/E
- -336.52
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -336.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,520 · 99.39%
- EPS
- $0.00 · 100.00%
- Op Income
- $-5,520
- FCF YoY
- 0.00%
- 52W High
- $0.48
- 52W Low
- $0.00
- 50D MA
- $0.03
- 200D MA
- $0.04
- Beta
- -1.41
- Avg Volume
- 65
Get TickerSpark's AI analysis on MLPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MLPH coverage
Recent articles, reports, and earnings notes.
No research on MLPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLPH report →Similar companies
Peers in the same neighborhood.